REVIEW
Accepted on 29 Nov 2024
VISTA in haematological malignancies: A review of the literature
doi 10.3389/fimmu.2024.1466839
- 531 views
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
17k
Total downloads
59k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
REVIEW
Published on 26 Aug 2024
Advances in understanding the role of immune checkpoint LAG-3 in tumor immunity: a comprehensive review
doi 10.3389/fonc.2024.1402837
- 881 views
MINI REVIEW
Published on 13 Aug 2024
Role of TIM-3 in ovarian cancer: the forsaken cop or a new noble
doi 10.3389/fimmu.2024.1407403
- 948 views
SYSTEMATIC REVIEW
Published on 11 Jul 2024
Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis
doi 10.3389/fimmu.2024.1375136
- 1,887 views
REVIEW
Published on 28 Mar 2024
Programmed cell death-ligand 2: new insights in cancer
doi 10.3389/fimmu.2024.1359532
- 1,530 views
- 1 citation
REVIEW
Published on 05 Mar 2024
Inhibitory receptors of plasmacytoid dendritic cells as possible targets for checkpoint blockade in cancer
doi 10.3389/fimmu.2024.1360291
- 2,069 views
- 2 citations
ORIGINAL RESEARCH
Published on 29 Feb 2024
CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts
doi 10.3389/fimmu.2024.1256766
- 2,511 views
- 2 citations
REVIEW
Published on 19 Feb 2024
Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers – how to push the gas after having released the brake
doi 10.3389/fimmu.2024.1357333
- 2,484 views
CORRECTION
Published on 23 Jan 2024
Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors
doi 10.3389/fimmu.2024.1365240
- 604 views
- 1 citation
REVIEW
Published on 17 Jan 2024
HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker
doi 10.3389/fimmu.2023.1285895
- 2,870 views
- 11 citations
SYSTEMATIC REVIEW
Published on 09 Jan 2024
Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
doi 10.3389/fimmu.2023.1332213
- 1,926 views
- 3 citations
ORIGINAL RESEARCH
Published on 12 Dec 2023
A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors
doi 10.3389/fimmu.2023.1311658
- 3,844 views
- 9 citations
Published in
Frontiers in Immunology
- Cancer Immunity and Immunotherapy
Participating Journals
Frontiers in Oncology
- 3.5 impact factor
- 6.2 citescore
Impact
- 59kTopic views
- 41kArticle views
- 17kArticle downloads